In five out of nine patients, specific tumor reactive CD4/CD8 + T lymphocytes were found in PBMC by the IFN-γ secretion assay, demonstrating that i.p. trAb therapy is able to induce a verifiable increase of autologous tumor reactive T lymphocytes. This evidence concerns the gene CD4 and neoplasm.